Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01733069 · ClinicalTrials.gov registry record
Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System
A clinical trial, sponsored by Gen-Probe, Incorporated.
- Completed
- Registry status
- 1,912
- Enrollment target
NCT01733069: Completed study, sponsored by Gen-Probe, Incorporated.
NCT01733069 is a clinical trial that has completed, run by Gen-Probe, Incorporated. The registered enrollment target is 1,912 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01733069 has completed, sponsored by Gen-Probe, Incorporated.
- COMPLETED
- Registry status
- 1,912 participants
- Enrollment target
Study Summary
The objectives of this study are to establish the performance characteristics of the AC2 (APTIMA Combo 2) Assay on the PANTHER System for the sample types cleared for use on the TIGRIS and DTS (Direct Tube Sampling) Systems and to demonstrate the repeatability and reproducibility of the AC2 Assay on the PANTHER System.
Primary Outcome
Count of participants having a positive or negative APTIMA Combo 2 assay result (sensitivity and specificity)
Interventions
- DEVICE APTIMA COMBO 2 Assay (AC2 Assay)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,912 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-02 |
What the finished NCT01733069 record still lists
NCT01733069 is an observational study that tracks outcomes without assigning an intervention. Its 1,912 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which APTIMA COMBO 2 Assay (AC2 Assay) is the first listed.
NCT01733069 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01733069 about?
NCT01733069 is a clinical study titled "Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System". The objectives of this study are to establish the performance characteristics of the AC2 (APTIMA Combo 2) Assay on the PANTHER System for the sample types cleared for use on the TIGRIS and DTS (Direct Tube Sampling) Systems and to demonstrate the repeatability and reproducibility of the AC2 Assay on...
What is the current status of trial NCT01733069?
This trial is currently completed. The enrollment target is 1,912 participants. The study started on 2010-11. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01733069?
The interventions under investigation include: APTIMA COMBO 2 Assay (AC2 Assay) (DEVICE).
Who is sponsoring clinical trial NCT01733069?
This trial is sponsored by Gen-Probe, Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT06799117 · 1,912 participants · NA
Adaptive Decision Support for Addiction Treatment Master
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia